Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023 Jun;5(6):100639. doi: 10.1016/j.xkme.2023.100639
Saigi-Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Choong E, Gholamrezaee M, Magistretti P, Aubry JM, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Kutalik Z, Conus P, Eap CB. Association of PCK1 with body mass index and other metabolic features in patients with psychotropic treatments. J Clin Psychopharmacol. 2015 Oct;35(5):544-52. doi: 10.1097/JCP.0000000000000388
Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, Schneeweiss S. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012 Feb 1;32(1):11-7.